Viking Therapeutics, Inc.
VKTX
$33.30
$0.100.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -194.66% | -66.80% | -43.94% | -10.68% | -15.73% |
| Total Depreciation and Amortization | 49.33% | 50.00% | 48.65% | 19.18% | 2.74% |
| Total Amortization of Deferred Charges | 33.33% | -14.29% | -7.69% | 1,100.00% | -43.75% |
| Total Other Non-Cash Items | 573.51% | 59.12% | 18.59% | 189.67% | -37.82% |
| Change in Net Operating Assets | 189.90% | -194.43% | -55.16% | -170.93% | -259.62% |
| Cash from Operations | -65.05% | -753.13% | -76.76% | -11.72% | -149.35% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 133.72% | 113.76% | -81.57% | 306.65% | 38.35% |
| Cash from Investing | 133.72% | 113.76% | -81.57% | 306.65% | 38.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -82.55% | -99.95% | 431.91% | -- | -98.93% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -82.55% | -99.94% | 431.91% | 3,508.11% | -98.91% |
| Foreign Exchange rate Adjustments | -500.00% | 102.08% | -248.00% | 57.35% | 200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 97.32% | -91.96% | -229.13% | 119.89% | -396.47% |